Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS · Delayed Price · Currency is USD
27.73
0.00 (0.00%)
Oct 31, 2025, 4:00 PM EDT
TKPHF Revenue
Takeda Pharmaceutical Company had revenue of 1.11T JPY in the quarter ending September 30, 2025, a decrease of -5.38%. This brings the company's revenue in the last twelve months to 4.42T, down -2.84% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.42T JPY
Revenue Growth
-2.84%
P/S Ratio
1.43
Revenue / Employee
93.08M JPY
Employees
47,455
Market Cap
42.56B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
Takeda Pharmaceutical Company News
- 2 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Benzinga
- 3 days ago - Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Benzinga
- 3 days ago - Takeda Pharmaceutical Company Limited 2026 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 days ago - Takeda Pharma H1 Net Profit Declines; Revenue Down 6.9% - Nasdaq
- 3 days ago - Takeda Pharmaceutical Q2 25 Earnings Conference Call At 6:00 AM ET - Nasdaq
- 3 days ago - Takeda Pharmaceutical (TAK) Adjusts Financial Guidance for FY2025 - GuruFocus